MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Clinical Oncology' source. Thu, 09 Feb 2012 03:37:27 +0100 http://www.medworm.com/index.php?rid=5669937&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665551200026X%2Fabstract%3Frss%3Dyes (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5669937 Thu, 09 Feb 2012 08:13:42 +0100 5669937 http://www.medworm.com/index.php?rid=5669936&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511009010%2Fabstract%3Frss%3Dyes Introduction: Androgen ablation (AA) is considered the standard initial therapy for men with high risk/metastatic prostate cancer. The role of chemotherapy and androgen ablation (TAA) is still undefined in this patient population. Here we present the clinical data from a phase II trial investigating clinical outcome and gene profiling of prostate cancer patients before and after AA or TAA. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5669936 Thu, 09 Feb 2012 08:13:42 +0100 5669936 http://www.medworm.com/index.php?rid=5669935&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511009009%2Fabstract%3Frss%3Dyes Introduction: Since PR07 and the Scandinavian Prostate Cancer Group showed survival benefit from adding radical radiotherapy (RT) to androgen deprivation therapy, prostate RT is routinely offered to fit patients with locally advanced prostate cancer [1,2]. Previously these patients were treated with hormones alone and followed up. Adding prostate RT when they become hormone refractory (and still have radiologically localised cancer) is controversial, but there is some evidence that patients with locally advanced hormone refractory prostate cancer (HRPC) may benefit [3]. The natural history of non-metastatic HRPC is unknown and treatment options are limited. Metastatic HRPC is associated with poor prognosis; widely quoted survival being 12–18 months, which with PSA lead time may be an und... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5669935 Thu, 09 Feb 2012 08:13:42 +0100 5669935 http://www.medworm.com/index.php?rid=5669934&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008995%2Fabstract%3Frss%3Dyes Introduction: Since December 2009 there has been a spinal cord compression coordinator in the Lancashire and Cumbria cancer network to enable patients to receive care as per NICE 2008 guidelines [1]. We conducted a retrospective analysis of patient management between December 2009 and January 2011 and reviewed survival outcomes. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5669934 Thu, 09 Feb 2012 08:13:42 +0100 5669934 http://www.medworm.com/index.php?rid=5669933&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008983%2Fabstract%3Frss%3Dyes Introduction: Evidence is in favour of localised radiotherapy in the treatment of LAPCa. Whether there is added disease control by including the pelvic lymph nodes in the irradiation volume is less clear. This paper describes our experience in using IMRT to treat the pelvic nodes in this patient population. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5669933 Thu, 09 Feb 2012 08:13:42 +0100 5669933 http://www.medworm.com/index.php?rid=5669932&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008971%2Fabstract%3Frss%3Dyes Introduction: Metastatic renal cell carcinoma (mRCC) has a poor prognosis. Treatment aims to improve progression free survival (PFS) and overall survival (OS). Sunitinib gained NICE approval in March 2009 as first line treatment and experience with it is growing. The NECN was the first in the UK to approve the use of Sunitinib in July 2007. This retrospective re-audit compares the NECN patient outcomes with published literature, updating previous NECN work from 2008. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5669932 Thu, 09 Feb 2012 08:13:42 +0100 5669932 http://www.medworm.com/index.php?rid=5669931&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665551100896X%2Fabstract%3Frss%3Dyes We report the outcomes for a cohort of men with higher risk prostate adenocarcinoma treated with LDR brachytherapy in a multi-institutional UK practice. Materials and methods: 217 men treated between 2003 and 2007 with iodine-125 brachytherapy at Christie, Leeds and Mount Vernon were identified from a multi-institutional database. Higher risk was defined as patients with≥2 D'Amico intermediate risk factors (PSA 10–20, GS 7 or clinical T2c) or ≥1 high risk factor (PSA>20, GS≥8). Kaplan–Meier methods were used to estimate biochemical relapse free survival (BRFS) defined using both Phoenix and ASTRO definitions. A univariate analysis was performed to assess the significance of Gleason score, PSA, T-stage, pre- or post-implant dosimetry, and additional hormones on BRFS. (Source: Cli... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5669931 Thu, 09 Feb 2012 08:13:42 +0100 5669931 http://www.medworm.com/index.php?rid=5669930&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008958%2Fabstract%3Frss%3Dyes We present a case series reporting acute radiotherapy toxicity in patients treated with primary HIFU. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5669930 Thu, 09 Feb 2012 08:13:41 +0100 5669930 http://www.medworm.com/index.php?rid=5669929&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008946%2Fabstract%3Frss%3Dyes Introduction: Evaluation of pelvic nodal external beam radiotherapy (EBRT) with interstitial high dose rate brachytherapy (HDRB) boost to prostate and seminal vesicles for high risk prostate adenocarcinoma. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5669929 Thu, 09 Feb 2012 08:13:41 +0100 5669929 http://www.medworm.com/index.php?rid=5669928&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008934%2Fabstract%3Frss%3Dyes We report our experience of medium-term toxicities following HDR brachytherapy as a single fraction boost of 12.5Gy or 15Gy prior to EBRT. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5669928 Thu, 09 Feb 2012 08:13:41 +0100 5669928 http://www.medworm.com/index.php?rid=5669927&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008922%2Fabstract%3Frss%3Dyes We present a preliminary analysis of a paired dataset in which mp-MRI was applied prior to a 5mm 3D template prostate mapping (TPM) in men at risk. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5669927 Thu, 09 Feb 2012 08:13:41 +0100 5669927 http://www.medworm.com/index.php?rid=5546586&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511009101%2Fabstract%3Frss%3Dyes The radiotherapy delivery service in England is emerging from a 25 year blight on strategic planning and forecasting of radiotherapy demand. Two of the most influential documents used as evidence for renovation and expansion in radiotherapy services are the Royal College of Radiologists (RCR) equipment, workload and staffing survey and the National Radiotherapy Advisory Group (NRAG) report . Where the RCR survey quantified significant variation in allocation and consumption of radiotherapy resources across England and Wales, the NRAG 2007 report generated national targets for radiotherapy service provision in terms of fraction burden (40,000 fractions per million of population by 2010 and up to 54,000 fractions per million by 2016) and the proportion of cancer patients receiving radiothera... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5546586 Thu, 29 Dec 2011 00:57:32 +0100 5546586 http://www.medworm.com/index.php?rid=5669921&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511009058%2Fabstract%3Frss%3Dyes Abstract: Aims: To update previous meta-analyses of randomised palliative radiotherapy trials comparing single fractions versus multiple fractions.Materials and methods: All published randomised controlled trials comparing single fraction versus multiple fraction schedules for the palliation of uncomplicated bone metastases were included in this analysis. Odds ratios and 95% confidence intervals were calculated for each trial. Forest plots were created using a random effects model and the Mantel–Haenszel statistic.Results: In total, 25 randomised controlled trials were identified. For intention-to-treat patients, the overall response rate was similar in patients receiving single fractions (1696 of 2818; 60%) and multiple fractions (1711 of 2799; 61%). Complete response rates were 620 of ... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5669921 Wed, 30 Nov 2011 05:00:00 +0100 5669921 http://www.medworm.com/index.php?rid=5669926&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008855%2Fabstract%3Frss%3Dyes Sir — The most effective treatment for patients with cervical cancer is concurrent chemoradiotherapy using cisplatin . However, this is not suitable for all patients. Over 5 years, 74 patients in our practice did not have cisplatin. We therefore reviewed the reasons for this and the results. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5669926 Fri, 11 Nov 2011 05:00:00 +0100 5669926 http://www.medworm.com/index.php?rid=5669925&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008843%2Fabstract%3Frss%3Dyes Sir — Glioblastoma multiforme (GBM) is an aggressive primary brain tumour. In 2005, a landmark European Organization for Research and Treatment of Cancer/National Cancer Institute Canada (EORTC/NCIC) trial showed that the addition of concomitant and adjuvant temozolomide to radical radiotherapy gives patients improved survival . The presence of MGMT promoter hypermethylation silences the MGMT gene, thereby reducing resistance to alkylating agents. This is associated with longer survival in patients who receive alkylating agents and is also an independent prognostic factor . (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5669925 Thu, 10 Nov 2011 05:00:00 +0100 5669925 http://www.medworm.com/index.php?rid=5546603&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008545%2Fabstract%3Frss%3Dyes We present a series of patients who received neoadjuvant chemotherapy with the TPF regimen before definitive surgical management. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5546603 Wed, 09 Nov 2011 05:00:00 +0100 5546603 http://www.medworm.com/index.php?rid=5368427&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008818%2Fabstract%3Frss%3Dyes (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5368427 Fri, 04 Nov 2011 05:53:17 +0100 5368427 http://www.medworm.com/index.php?rid=5368426&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008806%2Fabstract%3Frss%3Dyes (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5368426 Fri, 04 Nov 2011 05:53:17 +0100 5368426 http://www.medworm.com/index.php?rid=5546594&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008557%2Fabstract%3Frss%3Dyes Abstract: The global move towards more conformal radiotherapy for rectal cancer requires better imaging modalities that both visualise the disease accurately and are reproducible; to reduce interobserver variation. This review explores the advances in imaging modalities used in target volume delineation, with a view to make recommendations for current clinical practice and to propose future directions for research. A systematic review was conducted using MEDLINE and EMBASE. Articles considered relevant by the authors were included. Planning with orthogonal films is being replaced by computed tomography (CT) simulation. This is now considered the ‘gold standard’ and allows conformal three-dimensional planning. Magnetic resonance imaging (MRI) has been shown to overcome some of the limit... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5546594 Mon, 31 Oct 2011 04:00:00 +0100 5546594 http://www.medworm.com/index.php?rid=5546604&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008569%2Fabstract%3Frss%3Dyes Sir — Trastuzumab (Herceptin®) is a licensed monoclonal antibody used as adjuvant therapy for breast cancer patients where HER2 over-expression or gene amplification can be demonstrated. This case describes the occurrence of palmar plantar erythrodysaesthesia (PPE) as an extremely rare drug-related complication. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5546604 Mon, 24 Oct 2011 04:00:00 +0100 5546604 http://www.medworm.com/index.php?rid=5546602&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008533%2Fabstract%3Frss%3Dyes Sir — Secondary sarcomas due to radiation have long been recognised as a risk of successful cancer treatment. They are reported to typically manifest 10–20 years after radiation and the risk at 10 years after radiotherapy is reported in the range of 0.03–0.8% . Contemporary cancer treatments increasingly combine chemotherapy with radiation, either concurrently or sequentially. Little is known about the consequences of these treatments on the risk or time course of radiation-induced sarcomas. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5546602 Wed, 19 Oct 2011 04:00:00 +0100 5546602 http://www.medworm.com/index.php?rid=5546589&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008417%2Fabstract%3Frss%3Dyes Clinical oncology training has changed greatly over recent years. About 350 clinical oncology trainees are distributed across 20 training programmes in the UK, with one third of trainees working in London. Current trainees are a mix of year 4–5 specialist registrars, appointed before 2007 via the ‘old’ Calman training system, and ‘newer’ specialty registrars, appointed via the Modernising Medical Careers reform. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5546589 Mon, 10 Oct 2011 04:00:00 +0100 5546589 http://www.medworm.com/index.php?rid=5546596&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008399%2Fabstract%3Frss%3Dyes Conclusions: The utilisation rate of radiotherapy for rectal cancer increased significantly over time, particularly for preoperative radiotherapy and was most pronounced for T2–3 patients. Due to national multidisciplinary treatment guidelines, regional differences became limited in recent years after adjustment for age and stage of the disease. A low utilisation rate of radiotherapy was seen in women and elderly patients. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5546596 Tue, 04 Oct 2011 04:00:00 +0100 5546596 http://www.medworm.com/index.php?rid=5277303&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665551100817X%2Fabstract%3Frss%3Dyes Thursday 24th November & Friday 25th November 2011 Mount Vernon Hospital, Northwood, Middlesex This course aims to give an overview of brachytherapy physics and techniques, with the emphasis on ‘how to do it’. It is particularly aimed at trainee oncologists, but is also open to physicists, dosimetrists and radiographers. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5277303 Mon, 03 Oct 2011 19:47:34 +0100 5277303 http://www.medworm.com/index.php?rid=5669923&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008041%2Fabstract%3Frss%3Dyes Abstract: Aims: : To assess patients’ understanding of their illness and expectations of palliative radiotherapy for symptomatic metastases before and after consultation and to explore the relationship between response and demographics/Edmonton Symptom Assessment Scale (ESAS) scores.Materials and methods: In total, 100 participants completed a survey before and after consultation from March to October 2009. Descriptive statistics and statistical analyses were conducted to compare responses and to determine any relationship between responses and demographics or ESAS variables.Results: Up to 25% believed their cancer was curable; there was no change in belief that radiotherapy would cure their cancer (17% before and 15% after) or prolong their life (40% before and 45% after). There were si... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5669923 Mon, 03 Oct 2011 04:00:00 +0100 5669923 http://www.medworm.com/index.php?rid=5669916&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008363%2Fabstract%3Frss%3Dyes Conclusions: PET is recommended to improve the accuracy of M staging for the staging work-up of patients with oesophageal cancer who are potential candidates for curative therapy. Due to insufficient evidence, no recommendation was made for or against the use of PET for the assessment of treatment response and the evaluation of suspected recurrence. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5669916 Fri, 30 Sep 2011 04:00:00 +0100 5669916 http://www.medworm.com/index.php?rid=5546590&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008351%2Fabstract%3Frss%3Dyes Stage I seminoma accounts for 40–45% of testicular cancers , 800–900 UK cases annually . After orchidectomy, care includes one of three main options: adjuvant chemotherapy (one to two cycles of carboplatin), para-aortic radiotherapy or, as more than 80% of patients are cured by surgery , surveillance incorporating regular imaging. Relapse rates after adjuvant therapy are about 4–5% . However, salvage therapy is highly effective and cause-specific survival approaches 100%, irrespective of initial management . Given such excellent prospects, and the young age of patients, long-term implications and risks must be considered. Avoidance of treatment side-effects through the use of surveillance may be a sensible and safe approach. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5546590 Wed, 28 Sep 2011 04:00:00 +0100 5546590 http://www.medworm.com/index.php?rid=5669919&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008375%2Fabstract%3Frss%3Dyes Abstract: Aims: To assess the set-up uncertainty for gynaecological cancer patients treated with external beam radiation therapy using daily kilovoltage image guidance and to estimate set-up margins for treatment and factors that would predict higher set-up uncertainty.Materials and methods: Alignment data from daily two-dimensional kilovoltage planar images and three-dimensional kilovoltage cone beam images for 52 patients treated on a Varian 2300iX linear accelerator with On Board Imaging (OBI; version 1.4) capability were analysed. The mean displacements of translational shifts, population systematic errors and random errors were calculated. Using van Herk’s formula, the clinical target volume (CTV) to planning target volume (PTV) margins for set-up uncertainties were calculated. The ... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5669919 Mon, 26 Sep 2011 04:00:00 +0100 5669919 http://www.medworm.com/index.php?rid=5368425&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008053%2Fabstract%3Frss%3Dyes Sir — Preoperative staging for early stage non-small cell lung cancer is inconsistent. According to the National Comprehensive Cancer Network non-small cell lung cancer guidelines, preoperative brain imaging is not recommended for asymptomatic patients with stage IA disease . For the first time in the 3.2011 version, brain magnetic resonance imaging (MRI) for stage IB tumours is included as a National Comprehensive Cancer Network work-up recommendation with a category 2B designation. A more thorough search for distant metastasis may benefit patients, especially those with adenocarcinoma . (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5368425 Mon, 26 Sep 2011 04:00:00 +0100 5368425 http://www.medworm.com/index.php?rid=5368414&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665551100803X%2Fabstract%3Frss%3Dyes Continuing professional development (CPD) is the process by which doctors keep their knowledge and skills up to date throughout their working lives. The importance of CPD was first outlined in a number of National Health Service (NHS) documents in 1998–2000 and CPD remains one of the key elements of the General Medical Council revalidation process due to be implemented in 2012, albeit with a difference — there is a shift of emphasis from the purely ‘time spent’ model to a more ‘reflective’ model whereby doctors are required to evaluate what they have learned from their CPD activity and how it may affect and improve their performance. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5368414 Mon, 26 Sep 2011 04:00:00 +0100 5368414 http://www.medworm.com/index.php?rid=5546601&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008028%2Fabstract%3Frss%3Dyes Sir — Pemetrexed is an anti-folate agent proved to inhibit multiple folate-dependent enzymatic pathways. The US Food and Drug Administration has approved pemetrexed for the treatment of patients withnon-small cell lung cancer (NSCLC) and for the treatment of patients with mesothelioma. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5546601 Mon, 19 Sep 2011 04:00:00 +0100 5546601 http://www.medworm.com/index.php?rid=5546591&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511007916%2Fabstract%3Frss%3Dyes Abstract: The low incidence of testicular tumours and the fact that they show an extremely high diversity means that they may be poorly understood. Knowledge of the range of tumours and the differences in treatment available is essential for appropriate management. The advent of cisplatin chemotherapy and the exquisite sensitivity of seminoma to radiotherapy have resulted in excellent cure rates. Nevertheless, research has continued unabated, particularly to understand the molecular basis of germ cell tumours and why certain tumours are recalcitrant to treatment. This overview is an attempt to demystify areas of confusion and highlight areas of current interest in testicular pathology and oncology. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5546591 Mon, 19 Sep 2011 04:00:00 +0100 5546591 http://www.medworm.com/index.php?rid=5368424&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008065%2Fabstract%3Frss%3Dyes Sir — We would like to commend Heath et al. for their timely publication detailing the clinically significant role of human papillomavirus-16 (HPV16) in squamous cell carcinoma of the head and neck within the UK. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5368424 Mon, 19 Sep 2011 04:00:00 +0100 5368424 http://www.medworm.com/index.php?rid=5277287&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511007667%2Fabstract%3Frss%3Dyes This pair of editorials considers the early years of training. These years begin at medical school, where students are exposed to a large number of specialties, each of which has to compete for talent. Specialities that have helicopters landing on the hospital roof have an obvious initial advantage, but the best recruitment tool is excellent teaching; if we can deliver this, we will attract the best students. First, Luke Hughes-Davies discusses medical school teaching and then Jane Barrett considers the next step: recruitment into our training programmes. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5277287 Mon, 19 Sep 2011 04:00:00 +0100 5277287 http://www.medworm.com/index.php?rid=5669922&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008016%2Fabstract%3Frss%3Dyes Abstract: Aims: To assess health-related quality of life (HRQOL) after palliative radiotherapy for painful bone metastases using a palliative questionnaire (European Organization for Research and Treatment of Cancer QLQ-C15-PAL).Materials and methods: Patients scheduled to receive palliative radiotherapy for painful bone metastases (n=178) completed the QLQ-C15-PAL questionnaire before treatment and at week 1, week 2, month 1 and month 2 after the first day of radiotherapy. A partial response (PR) or a complete response (CR) to radiotherapy was defined according to the International Consensus criteria. General linear regression was used to analyse changes in QOL in the entire cohort and within responders and non-responders to radiotherapy at all follow-up periods.Results: The overall radio... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5669922 Wed, 14 Sep 2011 04:00:00 +0100 5669922 http://www.medworm.com/index.php?rid=5368418&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511008004%2Fabstract%3Frss%3Dyes Conclusion: This is the first report of three-dimensional high dose rate IGBT for the treatment of cervical cancer using a hybrid MRI/CT approach. Early results have shown the feasibility of this approach with excellent local control. Additional studies are needed to assess long-term outcomes of local control and associated morbidities. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5368418 Mon, 12 Sep 2011 04:00:00 +0100 5368418 http://www.medworm.com/index.php?rid=5187099&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511007904%2Fabstract%3Frss%3Dyes Monday 21 - Wednesday 23 November 2011 The Møller Centre, Cambridge (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5187099 Sat, 03 Sep 2011 20:51:06 +0100 5187099 http://www.medworm.com/index.php?rid=5187098&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511007692%2Fabstract%3Frss%3Dyes (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5187098 Sat, 03 Sep 2011 20:51:06 +0100 5187098 http://www.medworm.com/index.php?rid=5187097&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511007680%2Fabstract%3Frss%3Dyes (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5187097 Sat, 03 Sep 2011 20:51:06 +0100 5187097 http://www.medworm.com/index.php?rid=5546593&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511007679%2Fabstract%3Frss%3Dyes Abstract: The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. This review focuses on locally advanced prostate cancer and the evidence for treatment outcomes, both toxicity and efficacy, across the three major treatment modalities of external beam ra... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5546593 Mon, 29 Aug 2011 04:00:00 +0100 5546593 http://www.medworm.com/index.php?rid=5277302&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665551100759X%2Fabstract%3Frss%3Dyes Monday 21 - Wednesday 23 November 2011 The Møller Centre, Cambridge (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5277302 Mon, 29 Aug 2011 04:00:00 +0100 5277302 http://www.medworm.com/index.php?rid=5669915&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511007655%2Fabstract%3Frss%3Dyes Oesophageal cancer remains a poor prognosis disease and most patients present with either locally advanced or metastatic disease, typically with poor functional status, and are unsuitable for aggressive therapies. The incidence of oesophageal cancer has doubled in the last two decades throughout the world, and the age-standardised 5 year relative survival ratio in the UK remains dismal at 8%, with a 1 year survival rate of 27–30%. There is no effective potentially curative therapy that is not aggressive. Oeosphagectomy, in particular, has considerable morbidity, even as the procedure becomes predominantly laparoscopic so-called ‘minimally invasive’, with grade III toxicity in up to 40% of patients and a fearsome list of potential complications, including anastomotic leak (12%), pneu... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5669915 Wed, 24 Aug 2011 04:00:00 +0100 5669915 http://www.medworm.com/index.php?rid=5546595&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511007588%2Fabstract%3Frss%3Dyes The fifth National Colorectal Cancer Consensus Meeting was held at the Royal College of Physicians in London on 2 December 2010. The audience included doctors (16.2%), nurses (33.8%), pharmacists (11.8%), cancer network representatives (4.4%), patients (11.8%) and other delegates (22.1%), following the pattern of previous years . (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5546595 Tue, 16 Aug 2011 04:00:00 +0100 5546595 http://www.medworm.com/index.php?rid=5368417&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511007618%2Fabstract%3Frss%3Dyes Abstract: Aims: Image-guided brachytherapy (IGBT) is the new gold standard for cervix cancer brachytherapy. In 2009, the Royal College of Radiologists (RCR) published a guidance document to facilitate the implementation of IGBT for cervix cancer in the UK. This paper reports the progress since the publication of the RCR document.Materials and methods: Questionnaires were sent to 45 UK centres known to offer brachytherapy for cervix cancer in 2011. Replies were received from 43 (96%) centres. Details collected included brachytherapy machine, imaging technique for brachytherapy planning, applicator design and total dose to point A from external beam radiotherapy and brachytherapy. The results were compared with the 2008 survey reported in the RCR document.Results: The number of centres offer... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5368417 Tue, 16 Aug 2011 04:00:00 +0100 5368417 http://www.medworm.com/index.php?rid=5368413&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511007606%2Fabstract%3Frss%3Dyes Following the public enquiry into excess mortality at the Bristol Royal Infirmary in 2001 and the criminal acts of Harold Shipman, there was strong pressure for an improved system of regulation for doctors in the UK. The White Paper Trust, assurance and safety: the regulation of health professionals in 2007 suggested a formal process of revalidation to ensure that doctors were fit to practise and were safe. With some of the more complex and costly schemes discarded after the House of Commons Select Committee on Health 2011 , the proposal is now for enhanced annual appraisal. A sign off process on a 5 year cycle to the General Medical Council for doctors, through a linked ‘Responsible Officer’ will allow them to remain licensed. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5368413 Tue, 16 Aug 2011 04:00:00 +0100 5368413 http://www.medworm.com/index.php?rid=5368423&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511007576%2Fabstract%3Frss%3Dyes Sir — Cutaneous squamous cell carcinomas (CSC) exhibit strong cell surface expression of epidermal growth factor receptor (EGFR) . Anti-EGFR targeted therapy plus radiotherapy regimens have shown greater efficacy than radiotherapy alone in locally advanced head and neck squamous cell carcinoma . A review of published studies found case reports consistent with the efficacy of cetuximab (CTX) as a single-agent therapy in CSC and a phase II study reported the efficacy of CTX alone in advanced CSC . (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5368423 Wed, 10 Aug 2011 04:00:00 +0100 5368423 http://www.medworm.com/index.php?rid=5277301&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511007564%2Fabstract%3Frss%3Dyes Sir — Consensus guidelines for elective nodal contouring in head and neck cancer have been widely adopted, but there is considerable variation in high dose volume definition around the primary gross tumour volume (GTV) . Recommendations published in 2002 by the American Society for Therapeutic Radiology and Oncology recommended that the high dose level should be confined to the GTV with an appropriate uncertainty margin and the use of a lower intermediate dose (between the high and elective dose) to the surrounding anatomical region at high risk of subclinical disease (three dose level technique). However, alternative strategies range to the extreme of including all anatomical regions at high risk of subclinical disease within a single high dose volume, resulting in a two dose level tech... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5277301 Fri, 05 Aug 2011 04:00:00 +0100 5277301 http://www.medworm.com/index.php?rid=5187085&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511007278%2Fabstract%3Frss%3Dyes “In examinations, the foolish ask questions the wise cannot answer” Oscar Wilde, 1854–1900 This witty Irishman’s scathing analysis of examinations has a certain resonance with those of us who took professional examinations, such as FRCR, in days gone by, although our claim to wisdom might be overstated, as many have subsequently gone on to become the examiners. The Final FRCR examination in clinical oncology has changed from being the pre-eminent arbiter of fitness for the certificate of completion of training to having a collaborative role in a matrix of assessment, within a curriculum that provides a summative assessment of knowledge and competence across a variety of assessment methods. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5187085 Wed, 03 Aug 2011 23:00:00 +0100 5187085 http://www.medworm.com/index.php?rid=5082610&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665551100731X%2Fabstract%3Frss%3Dyes Thursday 24th November & Friday 25th November 2011 Mount Vernon Hospital, Northwood, Middlesex This course aims to give an overview of brachytherapy physics and techniques, with the emphasis on ‘how to do it’. It is particularly aimed at trainee oncologists, but is also open to physicists, dosimetrists and radiographers. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5082610 Mon, 01 Aug 2011 22:42:35 +0100 5082610 http://www.medworm.com/index.php?rid=5546597&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511007308%2Fabstract%3Frss%3Dyes Conclusions: Disparities exist in the receipt of treatment in stage II/III rectal cancer. Factors such as age, region of residence and stage should not be barriers to consulting an oncologist to discuss or receive treatment. The reasons for these disparities need to be identified and addressed. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5546597 Mon, 01 Aug 2011 04:00:00 +0100 5546597 http://www.medworm.com/index.php?rid=5277299&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511007291%2Fabstract%3Frss%3Dyes We would like to comment on the paper by Gwynne et al. . The authors state in the title that definitive chemoradiation for oesophageal cancer should be the standard of care. They also extend the statement to patients who are healthy enough to undergo surgical treatment (abstract, conclusion: ‘not only those with co-morbidity’). We believe that this paper presents no evidence to support such a statement. Apart from the lack of direct randomised trials comparing the methods, the authors did not include in their review landmark papers for surgical outcome, such as those by Hulscher et al. and Omloo et al. . These studies have achieved far better results for surgical patients, stage N1, where the 5 year survival was from 47 to 55% compared with 18.3% (median survival) in the present pap... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5277299 Fri, 29 Jul 2011 04:00:00 +0100 5277299 http://www.medworm.com/index.php?rid=5368416&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665551100714X%2Fabstract%3Frss%3Dyes Conclusion: This questionnaire has highlighted that AIA is a major patient concern. Further research, educational initiatives and guidance are needed to improve the management of this treatment complication. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5368416 Tue, 26 Jul 2011 04:00:00 +0100 5368416 http://www.medworm.com/index.php?rid=5277300&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665551100728X%2Fabstract%3Frss%3Dyes Sir — We thank Doulami and Theodorou for their response to our publication . The central message of this paper was that definitive chemoradiotherapy (dCRT) provides an alternative in those patients who are inoperable because of co-morbidities or locally advanced disease and dCRT can be considered a standard of care in these patients. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5277300 Mon, 25 Jul 2011 04:00:00 +0100 5277300 http://www.medworm.com/index.php?rid=5669920&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511007254%2Fabstract%3Frss%3Dyes Abstract: Aim: After the publication of several reports that the utilisation rate of radiotherapy for patients with non-small cell lung cancer (NSCLC) varies for both medical and non-medical reasons, the utilisation of radiotherapy was studied in four regions in the Netherlands.Materials and methods: Data from 1997–2008 were collected from the population-based cancer registries of four comprehensive cancer centres (‘regions’), which represent about half of the Dutch population, resulting in 24 185 non-metastatic patients with NSCLC. Treatment had to be started or planned within 6 months of diagnosis. We evaluated the utilisation of radiotherapy according to age, gender and period for each region.Results: The utilisation of radiotherapy alone decreased over time (from 35 to 19%), wher... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5669920 Fri, 22 Jul 2011 04:00:00 +0100 5669920 http://www.medworm.com/index.php?rid=5082609&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511007126%2Fabstract%3Frss%3Dyes Clinical Oncology is an international cancer journal covering all aspects of the clinical management of cancer patients, reflecting a multidisciplinary approach to therapy. We have a number of vacancies arising on the Editorial Board from November 2011 and applications for appointment to the Board are invited. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5082609 Thu, 21 Jul 2011 23:00:00 +0100 5082609 http://www.medworm.com/index.php?rid=5546600&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511007242%2Fabstract%3Frss%3Dyes Conclusion: This planning technique produces clinically acceptable plans for most lung stereotactic body radiotherapy patients without the need to resort to more complex methods of treatment planning and delivery. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5546600 Mon, 18 Jul 2011 04:00:00 +0100 5546600 http://www.medworm.com/index.php?rid=5546598&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665551100687X%2Fabstract%3Frss%3Dyes Conclusion: HPV16 infection seems to be a clinically significant cause of oropharyngeal HNSCC in the UK and the collection of national data should be supported. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5546598 Fri, 15 Jul 2011 04:00:00 +0100 5546598 http://www.medworm.com/index.php?rid=5546588&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665551100690X%2Fabstract%3Frss%3Dyes Abstract: Aim: To assess the effect of patient physician trust on how British South Asian (BSA) and British White (BW) patients cope when diagnosed with cancer.Materials and methods: We administered a questionnaire incorporating domains of fidelity, honesty, competence, confidentiality and global trust. The patient–physician relationship most preferred by the patient was tested by a further five questions. Five other questionnaires were completed, including the Brief Illness Perception Questionnaire and mini-MAC. In total, 94 BSA patients and 185 BW patients were recruited in the Leicestershire Cancer Centre by an English-speaking nurse or two radiographers who between them spoke English, Gujarati, Hindi and Urdu.Results: In all the five domains of trust, BW and BSA patients rated doctor... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5546588 Mon, 11 Jul 2011 04:00:00 +0100 5546588 http://www.medworm.com/index.php?rid=5546587&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006881%2Fabstract%3Frss%3Dyes Conclusion: Our results show that there is a continual need for education about the causes of cancer both in BW and BSA patients. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5546587 Fri, 08 Jul 2011 04:00:00 +0100 5546587 http://www.medworm.com/index.php?rid=5546592&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006923%2Fabstract%3Frss%3Dyes Conclusions: We suggest that, for patients following a planned programme of appointments and investigations, physical examination rarely contributes to the detection of systemic relapse in the follow-up of testicular germ cell tumours. It may therefore be possible to reconfigure follow-up to focus on investigations and telephone contact. We estimate that this change might be appropriate for 40% of attendances and might be welcomed by patients, many of whom find follow-up burdensome. If such a change were considered, patient education would be essential to ensure continuing compliance with the follow-up protocol. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5546592 Mon, 04 Jul 2011 04:00:00 +0100 5546592 http://www.medworm.com/index.php?rid=5082594&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006911%2Fabstract%3Frss%3Dyes As with all things in medicine, medical education continues to change. The introduction of curricula with clear learning objectives is aimed at ensuring that by the end of specialty training doctors are prepared to take up a consultant post in their chosen specialty. The completion of specialty training is, however, one milestone in a medical career that requires lifelong learning and development. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5082594 Sun, 03 Jul 2011 23:00:00 +0100 5082594 http://www.medworm.com/index.php?rid=4988511&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511007096%2Fabstract%3Frss%3Dyes (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4988511 Sat, 02 Jul 2011 01:32:51 +0100 4988511 http://www.medworm.com/index.php?rid=5669918&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006893%2Fabstract%3Frss%3Dyes Conclusions: The power of the study to detect differences was limited by the below target sample size and poor compliance. Further research is recommended, taking cognisance of the factors contributing to the limitations of this study. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5669918 Thu, 23 Jun 2011 04:00:00 +0100 5669918 http://www.medworm.com/index.php?rid=5277298&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006935%2Fabstract%3Frss%3Dyes Sir — Tamoxifen is a major contributor to the recent decline in mortality from hormone receptor-positive early breast cancer and is well tolerated by most patients . Despite a wealth of data reported from clinical trials, quality of life (QoL) outcomes have not been reported over the specific time of treatment withdrawal. Tamoxifen withdrawal could have a positive effect on QoL if tamoxifen-related side-effects are relieved or it could have a negative effect if the withdrawal of the psychological security of taking tamoxifen reduces QoL. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5277298 Thu, 23 Jun 2011 04:00:00 +0100 5277298 http://www.medworm.com/index.php?rid=5368420&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006856%2Fabstract%3Frss%3Dyes Conclusion: Data from the above studies are potentially conflicting and inconclusive for defining the optimal neoadjuvant treatment schedule. In our opinion, the above question can only be answered within the context of a randomised control trial. We have included a proposal for a trial design for direct comparison of these modalities. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5368420 Mon, 20 Jun 2011 04:00:00 +0100 5368420 http://www.medworm.com/index.php?rid=4988506&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006030%2Fabstract%3Frss%3Dyes Abstract: Cancer-induced bone pain (CIBP) is common and challenging to treat. Common therapies, such as opioids, radiotherapy and bisphosphonates, are often only partially effective. CIBP is a different entity to inflammatory or neuropathic pain and needs to be considered as such. This overview examines the mechanisms of CIBP; the imbalance of bone turnover, peripheral and central nervous involvement and key neurochemical mediators. The current understanding of the underlying pathophysiology of CIBP is discussed. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4988506 Thu, 16 Jun 2011 23:00:00 +0100 4988506 http://www.medworm.com/index.php?rid=5187096&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006868%2Fabstract%3Frss%3Dyes Sir — We read with interest the recent debate on concurrent chemoradiotherapy for non-small cell lung cancer . We would like to report our experience of treating non-small cell lung cancer with hypofractionated, accelerated radiotherapy and concurrent cisplatin/vinorelbine chemotherapy (SOCCAR regimen) in the Beatson West of Scotland Cancer Centre. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5187096 Tue, 14 Jun 2011 23:00:00 +0100 5187096 http://www.medworm.com/index.php?rid=5368422&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006844%2Fabstract%3Frss%3Dyes Conclusions: Despite their limited lifespan, patients reported pain relief after palliative radiotherapy. Patients suffering from painful bone metastases with an estimated survival of 3 months should still be considered for palliative radiotherapy. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5368422 Mon, 13 Jun 2011 04:00:00 +0100 5368422 http://www.medworm.com/index.php?rid=5277288&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006819%2Fabstract%3Frss%3Dyes The systematic review of Wright and colleagues addresses two important issues for patients with primary cutaneous melanoma of the trunk and extremities: the width of primary excision margins and the use of sentinel lymph node biopsy (SLNB). (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5277288 Thu, 09 Jun 2011 04:00:00 +0100 5277288 http://www.medworm.com/index.php?rid=5669924&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006832%2Fabstract%3Frss%3Dyes Abstract: Aims: The prevalence of anxiety and depression in patients with advanced cancer has been reported to be on average 25% and to significantly affect patients’ quality of life. Despite high prevalence rates, these disorders remain underdiagnosed and undertreated. The purpose of our study was to examine the self-report rates of anxiety and depression with the Edmonton Symptom Assessment System (ESAS) and to assess the predictive factors for these reports in cancer patients with metastatic disease.Materials and methods: Consecutive patients who attended the Rapid Response Radiotherapy Program (RRRP) completed the ESAS as well as baseline demographic information. Ordinal logistic regression analysis was used to determine factors that significantly predicted anxiety and/or depression.... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5669924 Wed, 08 Jun 2011 04:00:00 +0100 5669924 http://www.medworm.com/index.php?rid=5368419&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006820%2Fabstract%3Frss%3Dyes Conclusions: Our population-level outcomes are in keeping with published observed results and provide some of the first Canadian population-level data on HDR and LDR outcomes. We found no significant different in cause-specific survival between patients managed with HDR and LDR, although interpretation is limited by patient numbers. Our results for external beam radiotherapy alone emphasise the vital role brachytherapy plays in the management of cervical cancer. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5368419 Mon, 06 Jun 2011 04:00:00 +0100 5368419 http://www.medworm.com/index.php?rid=5368415&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006741%2Fabstract%3Frss%3Dyes Abstract: Aims: The effect of patient- and treatment-related factors in the development of late normal tissue toxicity after radiotherapy is not yet fully established. The aim of this study was to elucidate the relative importance of such factors in the development of late toxicity after breast-conserving surgery and adjuvant breast radiotherapy.Materials and methods: Patient- and treatment-related factors were analysed in 1014 patients who had received adjuvant radiotherapy to the breast in the Cambridge Breast Intensity-modulated Radiotherapy (IMRT) Trial. Late toxicity data were collected using photographic and clinical assessments and patient-reported questionnaires at 2 years after radiotherapy.Results: On multivariate analysis, a larger breast volume was statistically significantly a... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5368415 Mon, 06 Jun 2011 04:00:00 +0100 5368415 http://www.medworm.com/index.php?rid=4988504&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006807%2Fabstract%3Frss%3Dyes To most patients, a diagnosis of cancer goes hand in hand with an expectation of having pain, and this expectation is usually that pain will be severe and poorly controlled. Although we know that the prevalence of pain increases with disease progression, with rates of 70–90% in patients with advanced disease, patients’ fears that pain will be severe and poorly controlled should be ill-founded. There are many reasons, however, why patients may not achieve good pain control. These may be divided into professional and patient factors, knowledge and attitudes. In order for pain to be managed well it needs to be assessed properly, so that its underlying mechanism can be diagnosed and treated, if possible, and the response to treatment can be judged. Knowledge of the pathophysiology of cance... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4988504 Wed, 01 Jun 2011 23:00:00 +0100 4988504 http://www.medworm.com/index.php?rid=5277290&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006777%2Fabstract%3Frss%3Dyes Conclusions: En bloc surgery was a prognostic factor on outcomes for local control and survival in this series. Data from the literature have shown that postoperative radiation therapy improves local control. Most series were carried out with conventional fractionation. The effect of planned breaks (split-course radiotherapy) may be deleterious, as suggested in this series. Therefore, split-course radiotherapy cannot be recommended for SHNMM. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5277290 Mon, 30 May 2011 04:00:00 +0100 5277290 http://www.medworm.com/index.php?rid=5368421&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006789%2Fabstract%3Frss%3Dyes Abstract: The use of chemotherapy in the treatment of prostate cancer is a relatively recent development, with no published data on the patterns of care in the UK. We carried out a population-based study to assess variation in the use of prostate cancer chemotherapy over time in a UK cancer network. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5368421 Wed, 25 May 2011 04:00:00 +0100 5368421 http://www.medworm.com/index.php?rid=5277289&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006753%2Fabstract%3Frss%3Dyes Conclusions: Excision margins range from 5mm to 2cm depending on the melanoma depth. Patients with a melanoma greater than 1.0mm in thickness should be given the opportunity to discuss sentinel lymph node biopsy to provide staging and prognostic information. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5277289 Wed, 25 May 2011 04:00:00 +0100 5277289 http://www.medworm.com/index.php?rid=4988510&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006790%2Fabstract%3Frss%3Dyes Abstract: Inter-individual variation in response to opioids for cancer pain is a well-established phenomenon. Variation occurs in the dose of opioid required, the analgesic efficacy of the opioid and also in the side-effects experienced by the individual taking the drug. To date, no clinical factor has been identified that can reliably explain or predict such variation. In recent years there has been growing interest in the possibility that genetic factors may play a role in the variability in opioid response. The aims of this review are to present the evidence supporting pharmacogenetic research in this area, to evaluate some of the studies and results that have been published to date and to present some of the challenges for future research in this area. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4988510 Tue, 24 May 2011 23:00:00 +0100 4988510 http://www.medworm.com/index.php?rid=5277297&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006686%2Fabstract%3Frss%3Dyes Conclusion: This randomised trial encountered the accrual difficulties and consequent low statistical power commonly associated with interdisciplinary studies drawing from a small eligible population, but can contribute to future overviews on the management of solitary brain metastases. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5277297 Wed, 18 May 2011 04:00:00 +0100 5277297 http://www.medworm.com/index.php?rid=5187095&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665551100673X%2Fabstract%3Frss%3Dyes Sir — I would like to share our experience about a patient who developed symptoms and signs of alcohol intoxication with the new formulation of docetaxel, which contains a 2.2-fold higher quantity of ethanol. It was introduced in September 2009 to simplify the preparation of the infusion solution . (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5187095 Sun, 15 May 2011 23:00:00 +0100 5187095 http://www.medworm.com/index.php?rid=5082608&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006248%2Fabstract%3Frss%3Dyes Sir — Bevacizumab is a monoclonal antibody that recognises vascular endothelial growth factor receptor A and has been shown to increase overall survival when added to standard chemotherapy regimens in patients with metastatic colorectal cancer. Its toxicity profile is different from standard chemotherapy. Among its risk factors, idiopathic gastrointestinal perforation is a recognised hazard: a 28 day free period between the operation and drug initiation is recommended. We have encountered a late anastomotic dehiscence 3 years after surgery. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5082608 Sun, 15 May 2011 23:00:00 +0100 5082608 http://www.medworm.com/index.php?rid=4988509&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006376%2Fabstract%3Frss%3Dyes Abstract: Patients with cancer frequently experience pain, and even with increased modern knowledge and skills in drug and other therapy, this pain is poorly controlled in a significant proportion. For these patients, a range of interventional techniques can play a significant role in providing pain relief. These include neuraxial administration of opioids and other drugs, temporary or permanent blockade of nerve pathways and minimally invasive management of bony and other metastases. Those involved in the treatment of pain from cancer should be aware of the scope of these techniques and ready to call upon specialists in their use. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4988509 Sun, 15 May 2011 23:00:00 +0100 4988509 http://www.medworm.com/index.php?rid=4988505&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006674%2Fabstract%3Frss%3Dyes Abstract: Pain has been studied in depth for decades, yet the pain associated with cancer is still frequently under treated. The measurement of pain in patients with terminal cancer is imperative, because failure to carry it out is recognised as an important reason for inadequate treatment. Although pain is characterised as a symptom, it is a subjective personal experience or a perception. This perception is influenced by both nociceptive transmission and central nervous system modulation; and psychological, social and other environmental factors. It is a complex issue most simply described by the phrase ‘Pain is whatever the experiencing person says it is, existing whenever he says it does’. With such complex interplays between pathophysiological and biopsychosocial factors, it is uns... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4988505 Sun, 15 May 2011 23:00:00 +0100 4988505 http://www.medworm.com/index.php?rid=4808770&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006352%2Fabstract%3Frss%3Dyes Thursday 24th November & Friday 25th November 2011 Mount Vernon Hospital, Northwood, Middlesex This course aims to give an overview of brachytherapy physics and techniques, with the emphasis on ‘how to do it’. It is particularly aimed at trainee oncologists, but is also open to physicists, dosimetrists and radiographers. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4808770 Wed, 11 May 2011 23:40:48 +0100 4808770 http://www.medworm.com/index.php?rid=5277292&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006388%2Fabstract%3Frss%3Dyes Conclusion: No significant benefit has been shown for the use of four-dimensional computed tomography-based planning if motion management is not implemented concurrently with a reduced posterior margin between clinical and planning target volumes. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5277292 Mon, 09 May 2011 04:00:00 +0100 5277292 http://www.medworm.com/index.php?rid=5187092&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006364%2Fabstract%3Frss%3Dyes Conclusions: Clinical oncologists recognise late-onset bowel dysfunction after pelvic radiotherapy as a significant problem, but one that is linked to poor recognition of symptoms and an inadequate patchy service. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5187092 Sun, 08 May 2011 23:00:00 +0100 5187092 http://www.medworm.com/index.php?rid=5187088&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006340%2Fabstract%3Frss%3Dyes Conclusions: There was a strong agreement between patients, their companions and members of the MDT with regards to priorities in head and neck cancer outcomes and low post-treatment regret for patients and their companions. These results suggest that the patients’ companions and members of the MDT are able to exercise good judgment when it comes to supporting patients in decision making. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5187088 Sun, 08 May 2011 23:00:00 +0100 5187088 http://www.medworm.com/index.php?rid=5277293&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006406%2Fabstract%3Frss%3Dyes Conclusion: Routine computed tomography staging of patients with locally advanced breast cancer is worthwhile with the inflammatory subtype of locally advanced disease having the higher risk of metastatic disease at presentation. Pleural-based metastatic disease is more likely in patients with the inflammatory subtype. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5277293 Fri, 06 May 2011 04:00:00 +0100 5277293 http://www.medworm.com/index.php?rid=5277296&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665551100625X%2Fabstract%3Frss%3Dyes Abstract: Radiological and nuclear medicine imaging modalities used for assessing bone metastases treatment response include plain and digitalised radiography (XR), skeletal scintigraphy (SS), dual-energy X-ray absorptiometry (DEXA), computed tomography (CT), magnetic resonance imaging (MRI), [18F] fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/CT. Here we discuss the advantages and disadvantages of these assessment modalities as evident through different clinical trials. Additionally, we present the more established response criteria of the International Union Against Cancer and the World Health Organization and compare them with newer MD Anderson criteria. Even though serial XR and SS have been used to assess the therapeutic response for decades, several months are req... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5277296 Mon, 02 May 2011 04:00:00 +0100 5277296 http://www.medworm.com/index.php?rid=5187091&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006212%2Fabstract%3Frss%3Dyes Conclusion: An experienced nurse, working within a defined scope of practice, with medical support can manage care in patients with mild or moderate symptoms arising after pelvic radiotherapy. An ongoing randomised controlled trial is assessing patient outcomes. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5187091 Sun, 01 May 2011 23:00:00 +0100 5187091 http://www.medworm.com/index.php?rid=5187094&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006418%2Fabstract%3Frss%3Dyes Sir — Differentiated thyroid cancer comprises less than 1% of all malignancies, but is the most common endocrine malignancy . It is highly curable with a good prognosis, with 5 year mortality rates as low as 1–2% in younger patients . Treatment is initially surgical with radioiodine ablation recommended for tumours greater than 1cm . Thyroid-stimulating hormone (TSH) suppression after radioiodine ablation is an important part of treatment. Tala and Tuttle published their protocol for TSH suppression in 2010 and recommended aggressive TSH suppression ( (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5187094 Thu, 28 Apr 2011 23:00:00 +0100 5187094 http://www.medworm.com/index.php?rid=5277291&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006339%2Fabstract%3Frss%3Dyes Abstract: The triple-negative class (oestrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor 2 [HER2]-negative) comprises about 15% of breast cancer. It is associated with a poor prognosis compared with tumours that are positive for hormone receptors or HER2. Despite being sensitive to chemotherapy, many women with metastatic triple-negative breast cancer (TNBC) relapse quickly, and commonly develop visceral metastasis, including lung, liver and brain metastasis. TNBC has molecular features that overlap with breast cancer in BRCA1 germline mutation carriers and with those of the basal-like molecular class of tumours. Furthermore, tumours with the triple-negative phenotype have specific features and express markers that are potential therapeuti... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5277291 Mon, 25 Apr 2011 04:00:00 +0100 5277291 http://www.medworm.com/index.php?rid=5187093&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665551100639X%2Fabstract%3Frss%3Dyes Sir — Reports of hypersensitivity reactions to oxaliplatin have been increasing. We have previously reported an overall incidence of 15% and grade 3–4 reactions of 2.2% , similar to what has been reported elsewhere. Different re-challenge and desensitisation protocols for oxaliplatin have been reported, mostly in the form of case reports or small case series. Currently, there is no established standard approach for re-challenging patients who have developed hypersensitivity reactions to oxaliplatin with the same drug. Patients may also develop more severe hypersensitivity reactions when being re-challenged with oxaliplatin, despite an increase in pre-medications . (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5187093 Sun, 24 Apr 2011 23:00:00 +0100 5187093 http://www.medworm.com/index.php?rid=5187087&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006236%2Fabstract%3Frss%3Dyes Conclusions: Good disease control in the neck can be achieved in patients with N2 HNSCC with SCRT. Post-treatment PET-CT has a high NPV. Neck dissection can be avoided if post-treatment PET-CT is negative. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5187087 Mon, 18 Apr 2011 23:00:00 +0100 5187087 http://www.medworm.com/index.php?rid=5187089&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006327%2Fabstract%3Frss%3Dyes Conclusion: At least a 3 year follow-up is required to accurately assess the outcome. The best effects of the treatment are achieved for small ( (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5187089 Sun, 17 Apr 2011 23:00:00 +0100 5187089 http://www.medworm.com/index.php?rid=5082595&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665551000453X%2Fabstract%3Frss%3Dyes Abstract: Aims: The primary aims of the Korean Hereditary Breast Cancer (KOHBRA) study are to estimate the prevalence of BRCA1/2 mutations and ovarian cancer among a high-risk group of patients with hereditary breast cancer and their families.Materials and methods: The KOHBRA study is a prospective multicentre cohort identifying cases and their families. Between May 2007 and May 2010, the KOHBRA study enrolled up to 2000 subjects. All participants received genetic counselling and BRCA genetic testing; the clinical information and blood samples for blood banking were collected. An interim analysis of the prevalence of BRCA1/2 mutations and ovarian cancer in Korean subjects was determined from the initial 975 patients who presented to 33 centres.Results: By April 2009, a total of 167 mutatio... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5082595 Sun, 17 Apr 2011 23:00:00 +0100 5082595 http://www.medworm.com/index.php?rid=5082601&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006315%2Fabstract%3Frss%3Dyes Patients experience ‘normal’ physiological pain after their peripheral nociceptive afferents are stimulated by tissue damage, and their nociceptive system activates to produce the experience of pain in the damaged area. By comparison, patients experience neuropathic pain when the same system produces pain in an area that paradoxically lacks actual tissue damage itself . Experts define neuropathic pain as ‘pain arising as a direct consequence of a lesion or disease affecting the somatosensory system’. It is classified as either central or peripheral, reflecting the origin of the underlying insult . (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5082601 Wed, 13 Apr 2011 23:00:00 +0100 5082601 http://www.medworm.com/index.php?rid=5277295&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006224%2Fabstract%3Frss%3Dyes Discussion: The measured prostate shifts with respect to bony anatomy and external marks after the first 10 imaging sessions were shown to provide adequate predictive power for defining patient-specific margins in future fractions without a need for ongoing computed tomography imaging. Different options for CBCT imaging schedule are proposed that will reduce the treatment session time and imaging dose to radiotherapy patients while ensuring appropriate prostate cover and normal tissue sparing. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5277295 Wed, 13 Apr 2011 04:00:00 +0100 5277295 http://www.medworm.com/index.php?rid=5082607&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006194%2Fabstract%3Frss%3Dyes Sir — In 2006, Bonner et al. compared radiotherapy with concurrent cetuximab (CtRT) with radiotherapy alone in the treatment of locally advanced head and neck squamous cell carcinoma (LAHNSCC). CtRT was associated with an improvement in overall survival of 20 months without any difference between groups in acute grade 3/4 in field toxicities or short-term quality of life. Matzinger et al. published a detailed review of concurrent chemoradiotherapy, including the use of CtRT for LAHNSCC, in 2009. The National Institute for Health and Clinical Excellence (NICE) issued guidance on the use of CtRT for LAHNSCC in 2008 for patients with an excellent Karnofsky performance status when platinum-based chemoradiotherapy is contraindicated. We have used CtRT in LAHNSCC from 2008 based on this gu... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5082607 Tue, 12 Apr 2011 23:00:00 +0100 5082607 http://www.medworm.com/index.php?rid=5082600&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511000021%2Fabstract%3Frss%3Dyes Conclusions: The 0-7-21 regimen provided effective and rapid symptomatic relief with acceptable toxicity, and offered the advantage of convenience for most patients. It offers an alternate treatment option for carefully selected patients with incurable gynaecological malignancies. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5082600 Sun, 10 Apr 2011 23:00:00 +0100 5082600 http://www.medworm.com/index.php?rid=5277294&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006017%2Fabstract%3Frss%3Dyes Abstract: Aims: A variety of dosimetric parameters have been shown to influence the incidence of late radiation toxicity. The effect of other treatment- and patient-related factors is less well established. The aim of this study was to elucidate the influence of such factors in the development of late symptoms after radical radiotherapy to the prostate.Materials and methods: Patient- and treatment-related factors that are thought to influence the development of late toxicity were analysed in 788 patients who had received radical radiotherapy to the prostate in the Medical Research Council RT01 trial. Late toxicity data were recorded using the Radiation Therapy Oncology Group, Late Effects of Normal Tissues/Subjective, Objective, Management, Analytic, Royal Marsden Hospital and the Universi... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5277294 Thu, 07 Apr 2011 04:00:00 +0100 5277294 http://www.medworm.com/index.php?rid=5082598&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665551100598X%2Fabstract%3Frss%3Dyes Abstract: Aim: To compare online position verification strategies with offline correction protocols for patients undergoing definitive prostate radiotherapy.Materials and methods: We analysed 50 patients with implanted fiducial markers undergoing curative prostate radiation treatment, all of whom underwent daily kilovoltage imaging using an on-board imager. For each treatment, patients were set-up initially with skin tattoos and in-room lasers. Orthogonal on-board imager images were acquired and the couch shift to match both bony anatomy and the fiducial markers recorded. The set-up error using skin tattoos and offline bone correction was compared with online bone correction. The fiducial markers were used as the reference.Results: Data from 1923 fractions were analysed. The systematic err... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5082598 Wed, 06 Apr 2011 23:00:00 +0100 5082598 http://www.medworm.com/index.php?rid=5082606&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006029%2Fabstract%3Frss%3Dyes Sir — We read with great interest the article by Murray et al. . The authors reported the results of carboplatin-based third-line chemotherapy in a relatively small and heterogeneous series of patients with recurrent high-grade gliomas (HGG): eight patients with grade III glioma and 18 patients with grade IV glioma (glioblastoma multiforme). They explained the low rate of partial response (12%) and disease stabilisation (19%) and the high rate of disease progression (69%) with the existence of a cross-resistance between carboplatin and temozolomide, but not between carboplatin and nitrosoureas. In our opinion, this is questionable. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5082606 Sun, 03 Apr 2011 23:00:00 +0100 5082606 http://www.medworm.com/index.php?rid=5187090&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005887%2Fabstract%3Frss%3Dyes Conclusions: Our results show a good response of recurrent medulloblastoma after interstitial brachytherapy. High rates of tumour remission were yielded with low rates of treatment-related morbidity. Thus, 125I seed brachytherapy should be considered as a treatment option for recurrent medulloblastoma. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5187090 Sun, 27 Mar 2011 23:00:00 +0100 5187090 http://www.medworm.com/index.php?rid=5082599&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005991%2Fabstract%3Frss%3Dyes Abstract: The aim of this overview was to assess the utility of various imaging technologies (fluoroscopy, ultrasound, computed tomography, magnetic resonance imaging and positron emission tomography) for the treatment planning of high dose rate brachytherapy for cervical cancer. Reviews and primary studies comparing different imaging technologies used during high dose rate brachytherapy for cervical cancer and published from 1988 to 2008 were sought by searching MEDLINE and EMBASE databases, the Cochrane Library, personal files and reference lists of identified studies, and by contacting experts. Study selection, study quality assessment and data extraction were carried out in duplicate. Twelve studies met the inclusion criteria. No systematic reviews or randomised controlled studies (RCT... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5082599 Sun, 27 Mar 2011 23:00:00 +0100 5082599 http://www.medworm.com/index.php?rid=4808755&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005978%2Fabstract%3Frss%3Dyes All my life, as down an abyss without a bottom, Ihave been pouring van loads of information into thatvacancy of oblivion I call my mind. Logan PearsallSmith, Anglo-American Essayist, 1865–1946. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4808755 Fri, 25 Mar 2011 00:00:00 +0100 4808755 http://www.medworm.com/index.php?rid=5082605&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511006005%2Fabstract%3Frss%3Dyes We report on a 70-year-old woman without prior cardiopulmonary disease who was admitted with progressive dyspnoea developing 4 days after the first doses of paclitaxel (175mg/m2) and trastuzumab (6mg/kg). She had received appropriate premedications and no immediate infusion reactions occurred. Two weeks earlier, she had finished dose dense AC for stage T1c N0M0, oestrogen receptor-positive, progesterone receptor-negative, HER-2-positive and grade 3/3 right breast invasive ductal carcinoma. About 6 months earlier, she had undergone a lumpectomy and a concurrent regimen (AC-TH-H) was selected. Her left ventricular ejection fraction (LVEF) was 70% before the initiation of chemotherapy. On physical examination, she was afebrile and hypoxic (80% on room air). There was jugular venous distension... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5082605 Mon, 21 Mar 2011 00:00:00 +0100 5082605 http://www.medworm.com/index.php?rid=4738478&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005413%2Fabstract%3Frss%3Dyes Abstract: The question whether radiation-induced thyroid cancer differs by its molecular biology from sporadic disease still remains. Studies on tissue from patients who developed thyroid cancer after the Chernobyl accident have provided a unique opportunity to look for biological consequences of low-dose irradiation by comparing the gene expression profile of sporadic papillary thyroid cancer (PTC), whose aetiology is unknown, and PTC induced by internal radiation. So far, four transcriptomic studies comparing radiation-induced and sporadic thyroid cancer have been reported. However, no final conclusion has been drawn regarding the presence of a radiation signature, as either no difference was noted or the reported differences were not sufficiently convincing due to the low number of case... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4738478 Wed, 16 Mar 2011 00:00:00 +0100 4738478 http://www.medworm.com/index.php?rid=4586101&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005243%2Fabstract%3Frss%3Dyes Background and purpose: The position of the prostate gland can vary due to factors such as rectal filling [1–5]. Our radiotherapy department uses margins from clinical target volume (CTV) to planning target volume (PTV) as small as 5mm. Using our department's current immobilisation, bowel preparation and verification methods, does this margin provide adequate CTV coverage throughout a course of radical radiotherapy to the prostate? (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586101 Tue, 15 Mar 2011 18:27:16 +0100 4586101 http://www.medworm.com/index.php?rid=4586100&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005231%2Fabstract%3Frss%3Dyes In this study, we explored the optimal pleural dose homogeneity that is achievable theoretically using Hi-Art Tomotherapy™ and RapidArc® (Varian). (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586100 Tue, 15 Mar 2011 18:27:16 +0100 4586100 http://www.medworm.com/index.php?rid=4586099&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665551100522X%2Fabstract%3Frss%3Dyes Introduction: In Australian radiation therapy, professionalism and competence are used as benchmarks for standards of acceptable practice. The notion of fitness to practise (FTP) is only now becoming recognised as a mechanism by which health care professions are regulated. Currently there is no clear definition of FTP and how it is measured. The aim of the study was to investigate how FTP is defined by Australian radiation therapists. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586099 Tue, 15 Mar 2011 18:27:16 +0100 4586099 http://www.medworm.com/index.php?rid=4586098&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005218%2Fabstract%3Frss%3Dyes Background: Most UK centres define treatment volumes for breast radiotherapy on a planning CT scan, although axillary and supraclavicular volumes are usually defined using bony landmarks. However, there is evidence that the position of lymph node location relative to bony landmarks varies according to patient position, in particular the degree of arm abduction. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586098 Tue, 15 Mar 2011 18:27:16 +0100 4586098 http://www.medworm.com/index.php?rid=4586097&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005206%2Fabstract%3Frss%3Dyes This study describes a retrospective planning comparison between IMRT and VMAT for STS. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586097 Tue, 15 Mar 2011 18:27:16 +0100 4586097 http://www.medworm.com/index.php?rid=4586096&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665551100519X%2Fabstract%3Frss%3Dyes Prior to the implementation of inverse-planned IMRT in our department, advanced planning techniques to improve conformity of dose distributions were developed for both prostate and head and neck treatment sites using the CMS/XiO treatment planning system. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586096 Tue, 15 Mar 2011 18:27:16 +0100 4586096 http://www.medworm.com/index.php?rid=4586095&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005188%2Fabstract%3Frss%3Dyes Introduction: Attenuation of beams through a treatment couch typically reduces dose by a few per cent, depending on beam angle, energy and couch type. This can make a significant difference to patient dose for treatments where the majority of the treatment is delivered through the couch. Accounting for this attenuation using hand calculations is prone to error, particularly when beams are not perpendicular to the couch. Accurate modelling of specific couches makes transferring patients between treatment machines with different couches problematic. A simplified model was developed in the planning software to account adequately for a range of couches to overcome these problems. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586095 Tue, 15 Mar 2011 18:27:16 +0100 4586095 http://www.medworm.com/index.php?rid=4586094&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005176%2Fabstract%3Frss%3Dyes Introduction: Checklists reduce errors when performing complex multi-step procedures. Although common in the airline and IT industries, they are increasingly being applied in healthcare, e.g. in surgery, through WHO and UK guidelines. The limitations of a paper checklist at our centre have prompted a move to a database checklist. A database checklist is inherently more flexible than paper, e.g. it can vary the checks required based on the treatment technique, clinical site etc. The data collected can also be analysed to improve treatment provision and patient safety. It is also ‘paperless’, conforming to the hospital's documentation strategy. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586094 Tue, 15 Mar 2011 18:27:16 +0100 4586094 http://www.medworm.com/index.php?rid=4586093&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005164%2Fabstract%3Frss%3Dyes We report our outcome and toxicity data in patients treated in this way. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586093 Tue, 15 Mar 2011 18:27:16 +0100 4586093 http://www.medworm.com/index.php?rid=4586092&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005152%2Fabstract%3Frss%3Dyes Introduction: Penile cancer is rare and one-third of patients present with locally advanced disease (T4 or nodal involvement) [1,2]. Despite treatment with a combination of penile and nodal surgery, radiotherapy and chemotherapy, outlook is poor (7–50% 5 year survival) with pelvic nodal involvement carrying a dismal prognosis ( (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586092 Tue, 15 Mar 2011 18:27:16 +0100 4586092 http://www.medworm.com/index.php?rid=4586091&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005140%2Fabstract%3Frss%3Dyes Aims: To assess the influence of the type of breast conserving surgery on postoperative clinical target volume (CTV) and the implications for breast radiotherapy planning. Methods: Patients undergoing breast conserving surgery at the Royal Cornwall Hospital (RCH) and recruited into the IMPORT LOW study investigating partial breast radiotherapy were analysed. Surgically placed titanium clips were sited at the superior, inferior, medial, lateral, anterior and posterior limits of the surgical field. This enabled accurate delineation of the CTV on postoperative CT scan performed for radiotherapy planning. Any differences between type of surgery and postoperative CTV, and the influence of a re-excision on the CTV were analysed by the Mann–Whitney U test. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586091 Tue, 15 Mar 2011 18:27:16 +0100 4586091 http://www.medworm.com/index.php?rid=4586090&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005139%2Fabstract%3Frss%3Dyes Background: An early prostate clinic (EPC) was set-up in 1997 in Cardiff involving urologists, oncologists, pathologists, radiologists and clinical nurse specialists. All patients referred have had central histopathological, radiological and clinical review prior to treatment and follow-up. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586090 Tue, 15 Mar 2011 18:27:16 +0100 4586090 http://www.medworm.com/index.php?rid=4586089&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005127%2Fabstract%3Frss%3Dyes This study reviewed the clinical guideline and examined the current clinical pathway to determine the local and wider implications of its implementation. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586089 Tue, 15 Mar 2011 18:27:16 +0100 4586089 http://www.medworm.com/index.php?rid=4586088&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005115%2Fabstract%3Frss%3Dyes Objectives: (1) To evaluate the frequency of repeat CT planning as a result of bladder deformation. (2) To establish the source of bladder deformation. Methods: Retrospective review of 149 patients treated between November 2006 and July 2010. Planning: Patients are asked to void their bladder immediately before scanning. The clinical target volume (CTV) is expanded by 1.5–2.0cm to produce a planned target volume (PTV) treated with a standard three- or four-field conformal technique (52.5–55Gy in 20 daily fractions). Treatment verification: CBCT acquired for the first three fractions, and reviewed at 10 and 15. Repeat CBCTs when: a set-up error >5mm is observed; changes in target volume shape or location are observed. All images reviewed online for gross errors and offline to allow cor... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586088 Tue, 15 Mar 2011 18:27:16 +0100 4586088 http://www.medworm.com/index.php?rid=4586087&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005103%2Fabstract%3Frss%3Dyes Introduction: In Leeds, cone beam CT (CBCT) has been a standard verification tool for lung conformal radiotherapy since 2007. Retrospective review demonstrated the need for repeat CT planning in 30% of patients. This justified a change in practice in 2009: moving from 3D to 4D CT planning. The work to be presented examines the impact of this change, and whether any further improvements could be made. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586087 Tue, 15 Mar 2011 18:27:16 +0100 4586087 http://www.medworm.com/index.php?rid=4586086&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005097%2Fabstract%3Frss%3Dyes Introduction: The radiotherapeutic management of prostate cancer is evolving. The CHHiP trial is investigating hypofractionation for localised prostate cancer. We have evaluated the safety of hypofractionated radiotherapy to the prostate and pelvic lymph nodes within a prospective clinical trial. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586086 Tue, 15 Mar 2011 18:27:16 +0100 4586086 http://www.medworm.com/index.php?rid=4586085&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005085%2Fabstract%3Frss%3Dyes Background and purpose: In patients receiving radical radiotherapy to the prostate, rectal distension can cause the prostate to shift [1–7], potentially leading to reduced PTV coverage and even biochemical failure [8]. A diet information sheet was developed with the aims of reducing rectal distension and minimising prostate movement. It included suggestions to increase the patients' fibre and fluid intake but reduce rectal gas. It was sent to patients due to receive radical radiotherapy to the prostate with their CT planning scan appointment letter. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586085 Tue, 15 Mar 2011 18:27:16 +0100 4586085 http://www.medworm.com/index.php?rid=4586084&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005073%2Fabstract%3Frss%3Dyes Introduction: The ACT-II trial confirmed mitomycin C with 5-FU as the standard of care for anal cancer when combined with conventionally planned radiotherapy. Capecitabine is widely used as an oral alternative to 5-FU in gastrointestinal cancer with encouraging preliminary results for anal cancer. Modern radiotherapy techniques allow greater dose shaping than with fields selected on the basis of macroscopic disease and bony anatomy. We sought to assess the toxicity and efficacy of a new regime using mitomycin C with capecitabine and conformally planned radiotherapy. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586084 Tue, 15 Mar 2011 18:27:16 +0100 4586084 http://www.medworm.com/index.php?rid=4586083&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005061%2Fabstract%3Frss%3Dyes We report the initial results of this phase I/II study, designed to prospectively assess the feasibility and efficacy of treating meningioma patients with IMRT. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586083 Tue, 15 Mar 2011 18:27:16 +0100 4586083 http://www.medworm.com/index.php?rid=4586082&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665551100505X%2Fabstract%3Frss%3Dyes Introduction: Despite the promise of IMRT, radiation induced xerostomia remains an important symptom affecting the quality of life of head and neck cancer survivors. There are no published guidelines on the optimum management of this condition. As part of the preparation for the NCRN ARIX trial of acupuncture in xerostomia we sought to understand the patterns of care for radiation induced xerostomia in the UK. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586082 Tue, 15 Mar 2011 18:27:16 +0100 4586082 http://www.medworm.com/index.php?rid=4586081&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005048%2Fabstract%3Frss%3Dyes The objective of this evaluation was to determine the pattern of recurrence following RT-TMZ. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586081 Tue, 15 Mar 2011 18:27:16 +0100 4586081 http://www.medworm.com/index.php?rid=4586080&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005036%2Fabstract%3Frss%3Dyes Introduction: Complex radiotherapy techniques require appropriate in vivo dosimetry approaches. This work sought to characterise two Elekta EPIDs to assess their suitability for use as in vivo dosimeters and to calibrate one EPID for isocentric point dose (IPD) measurements. This is part of a stepwise programme to use EPID dosimetry for more widespread in vivo applications. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586080 Tue, 15 Mar 2011 18:27:16 +0100 4586080 http://www.medworm.com/index.php?rid=4586079&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005024%2Fabstract%3Frss%3Dyes This study compares the incidence of acute bladder and rectal toxicity with and without FMs. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586079 Tue, 15 Mar 2011 18:27:16 +0100 4586079 http://www.medworm.com/index.php?rid=4586078&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005012%2Fabstract%3Frss%3Dyes This study evaluated an automatic segmentation tool (Brainlab iPlan®) in the delineation of nodal levels in patients with oropharyngeal cancer with regards to time taken, together with accuracy and reproducibility. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586078 Tue, 15 Mar 2011 18:27:16 +0100 4586078 http://www.medworm.com/index.php?rid=4586077&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511005000%2Fabstract%3Frss%3Dyes Purpose: At St James's Institute of Oncology (SJIO) we introduced stereotactic body radiotherapy (SBRT) into routine clinical practice for early lung cancer and present our initial results to determine feasibility and early outcomes. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586077 Tue, 15 Mar 2011 18:27:16 +0100 4586077 http://www.medworm.com/index.php?rid=4586076&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511004997%2Fabstract%3Frss%3Dyes Introduction: Stereotactic cranial radiotherapy relies on precise tumour relocation, achievable with the Gill–Thomas–Cosman frame. Patients unable to tolerate the frame can be immobilised using a thermoplastic shell, but relocation is less precise and larger margins are applied to create the planning target volume. The ExacTrac imaging system allows fast, accurate daily verification with low radiation dose. This improves the set-up accuracy of treatment using a shell. The set-up errors and the required set-up margin (SM) using daily ExacTrac stereoscopic image verification for patients in a shell were assessed and compared with those achieved for patients in a frame with the standard verification protocol (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586076 Tue, 15 Mar 2011 18:27:15 +0100 4586076 http://www.medworm.com/index.php?rid=4586075&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511004985%2Fabstract%3Frss%3Dyes Introduction: Set-up errors (SE) for prostate ± seminal vesicle (P±SV) radiotherapy with fiducial markers (FM) can be reduced using an on-line correction protocol. This enables set-up margin (SM) reduction. Additional time required for post-correction imaging may be problematic for busy radiotherapy departments and correcting errors below a certain tolerance may provide little benefit. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586075 Tue, 15 Mar 2011 18:27:15 +0100 4586075 http://www.medworm.com/index.php?rid=4586074&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511004973%2Fabstract%3Frss%3Dyes This study is a comparison of set-up correction data from both systems for head and neck patients treated with IMRT. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586074 Tue, 15 Mar 2011 18:27:15 +0100 4586074 http://www.medworm.com/index.php?rid=4586073&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511004961%2Fabstract%3Frss%3Dyes Introduction: There is increasing evidence, albeit from non-randomised studies, supporting SBRT as an improvement to conventional radiotherapy with respect to local control and possibly overall survival for patients with medically inoperable early stage peripheral non-small cell lung cancer. This technique has been in use in Middlesbrough since September 2009 with 18 patients planned to date. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586073 Tue, 15 Mar 2011 18:27:15 +0100 4586073 http://www.medworm.com/index.php?rid=4586072&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS093665551100495X%2Fabstract%3Frss%3Dyes Introduction: There has been a long standing need in Greater Manchester and Cheshire to increase capacity and improve local access to radiotherapy. Following an approved business proposal in 2008, The Christie embarked on the development of two satellite radiotherapy centres: at Oldham and Salford. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586072 Tue, 15 Mar 2011 18:27:15 +0100 4586072 http://www.medworm.com/index.php?rid=4586071&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511004948%2Fabstract%3Frss%3Dyes This study aims to compare the dosimetry of the two techniques in terms of dose homogeneity, target volume coverage and dose to organs at risk (OAR). (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586071 Tue, 15 Mar 2011 18:27:15 +0100 4586071 http://www.medworm.com/index.php?rid=4586070&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511004936%2Fabstract%3Frss%3Dyes Introduction: Palliative radiotherapy (RT) is a valuable treatment for patients with advanced lung cancer. Short courses of RT are effective for most patients [1]. 3D conformal planning is used to reduce toxicity to normal structures and to improve dose distribution across the target volume. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586070 Tue, 15 Mar 2011 18:27:15 +0100 4586070 http://www.medworm.com/index.php?rid=4586069&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511004924%2Fabstract%3Frss%3Dyes Purpose: To compare the planning target volume (PTV) coverage and doses to organs at risk between 3D conformal radiotherapy (3DCRT) and helical tomotherapy (HT) in two adult patients with Hodgkin lymphoma. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586069 Tue, 15 Mar 2011 18:27:15 +0100 4586069 http://www.medworm.com/index.php?rid=4586068&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511004912%2Fabstract%3Frss%3Dyes Introduction: Small cell cancer of the oesophagus is rare, frequently presents with metastases and generally has a poor prognosis. We undertook a retrospective analysis of patients treated in our network to try and identify the optimal treatment algorithm. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586068 Tue, 15 Mar 2011 18:27:15 +0100 4586068 http://www.medworm.com/index.php?rid=4586067&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511004900%2Fabstract%3Frss%3Dyes Introduction: Patients with advanced oesophageal cancer have a poor prognosis. Maintaining swallowing function is important for patients' quality of life. We reviewed our practice of using ‘consolidation’ radiation post chemotherapy in patients with advanced oesophageal cancer to see if this improves and maintains swallowing function. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586067 Tue, 15 Mar 2011 18:27:15 +0100 4586067 http://www.medworm.com/index.php?rid=4586066&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511004894%2Fabstract%3Frss%3Dyes Introduction: Approximately 30% of patients diagnosed with pancreatic cancer will present with locally advanced unresectable disease (LAPC). Improved planning techniques provide the opportunity for dose escalation. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586066 Tue, 15 Mar 2011 18:27:15 +0100 4586066 http://www.medworm.com/index.php?rid=4586065&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511004882%2Fabstract%3Frss%3Dyes Background: Oral mucositis is a frequent complication of radiotherapy in patients with head and neck cancer. Current products to treat symptoms are fairly inadequate. Two new products, MuGard™ and CaphosolR, have been used in some UK hospitals. MuGard™ is a viscous mucoadhesive rinse that provides a coating to the oral mucosa, (priced at £20+VAT for a 250 ml bottle) and CaphosolR is a supersaturated calcium phosphate oral rinse designed to moisten, lubricate and clean the oral cavity (priced at £32+VAT for a weekly pack). (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586065 Tue, 15 Mar 2011 18:27:15 +0100 4586065 http://www.medworm.com/index.php?rid=4586064&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511004870%2Fabstract%3Frss%3Dyes Introduction: Conformity achieved with IMRT is only valuable if we are confident with target position accuracy. IGRT should therefore be considered complimentary. This increases time on machine, critical in a busy centre, and limits the numbers of patients treated. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586064 Tue, 15 Mar 2011 18:27:15 +0100 4586064 http://www.medworm.com/index.php?rid=4586063&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511004869%2Fabstract%3Frss%3Dyes We present our single centre review of the tolerability and toxicity associated with TLI given as treatment for progressive BOS. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586063 Tue, 15 Mar 2011 18:27:15 +0100 4586063 http://www.medworm.com/index.php?rid=4586062&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511004857%2Fabstract%3Frss%3Dyes Introduction: Individual pre-treatment verification is carried out for all patients undergoing IMRT at UHNS. This is performed on a 2D ion chamber array. As the department wished to move to rotational therapy, an ArcCHECK™ 4D dosimetry system was purchased. The geometry of the system is cylindrical and allows the delivered dose to be evaluated in terms of gantry angle and real time. This is achieved by having 1386 diode detectors in a helical arrangement around the cylinder. The cylinder has a diameter of 26.6 cm and the diodes are set at a depth of 2.9 cm. A central cavity insert allows measurement of the isocentre dose with a traditional detector. The aim of the study was to evaluate the use of ArcCHECK™ for RapidArc® delivery in terms of its calibration, stability of calibration wi... Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586062 Tue, 15 Mar 2011 18:27:15 +0100 4586062 http://www.medworm.com/index.php?rid=4586061&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511004845%2Fabstract%3Frss%3Dyes Purpose: Retrospective comparison of the results after hyperfractionated radiotherapy for glioblastoma to conventionally fractionated treatment. Patients and methods: In total, 272 patients with glioblastoma were treated. The mean age at the beginning of radiotherapy was 61 years, the mean Karnofsky performance index was 70%, 55% of the patients had undergone tumour resection. Sixty-three per cent of the patients were applied hyperfractionated radiotherapy (HFR) giving single fractions of 1.5 Gy twice daily up to a total dose of 60 Gy within 4 weeks, whereas the remaining 37% received the same total dose conventionally in daily fractions of 2 Gy(CFR) within 6 weeks. No patient had neoadjuvant or concomitant chemotherapy. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586061 Tue, 15 Mar 2011 18:27:15 +0100 4586061 http://www.medworm.com/index.php?rid=4586060&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511004833%2Fabstract%3Frss%3Dyes Purpose: Retrospective evaluation of toxicity and results after radiochemotherapy (RCT) for glioblastoma. Patients and methods: Forty-four patients with glioblastoma received simultaneous RCT. The mean age at the beginning of therapy was 59 years, mean Karnofsky performance index 80%. A total dose of 60 Gy was applied within 6 weeks, 75 mg/m2/day temozolomide was given orally during the whole radiotherapy period. Adjuvant chemotherapy was performed in nine patients. This group was compared with a historical one having undergone radiotherapy (RT) with 60 Gy exclusively. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586060 Tue, 15 Mar 2011 18:27:15 +0100 4586060 http://www.medworm.com/index.php?rid=4586059&cid=s_35406_37_f&fid=35406&url=http%3A%2F%2Fwww.clinicaloncologyonline.net%2Farticle%2FPIIS0936655511004821%2Fabstract%3Frss%3Dyes Introduction: The treatment of complex superficial tumours presents a difficult challenge for conventional radiotherapy. Multiple field electron plans are resource intensive and technically problematic. This poster aims to show how TomoTherapy is an effective way of managing such treatments. (Source: Clinical Oncology) Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4586059 Tue, 15 Mar 2011 18:27:15 +0100 4586059